The lab equipment maker’s $5.2 billion acquisition of Patheon provides it with an avenue for growth but limited opportunities to cut costs.By ROBERT CYRAN from NYT
Business Day
Thermo Fisher Tests a Deal in Drug Production
The lab equipment maker’s $5.2 billion acquisition of Patheon provides it with an avenue for growth but limited opportunities to cut costs.By ROBERT CYRAN from NYT
Business Day
Posts
0 comments
Post a Comment